The FTSE 100 rose by 0.6%, propelled by surges in GSK and gold mining shares, as market focus shifted toward the Bank of ...
The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...
9d
Zacks.com on MSNEMA Accepts GSK's Filing for Depemokimab in Two Respiratory DiseasesGSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...
European shares saw a rise driven by healthcare giants GSK and Novo Nordisk following robust quarterly results. Novo Nordisk's strong profits from its drug Wegovy and GSK's share buyback plan boosted ...
2d
Zacks.com on MSNGSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term OutlookGSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...
The bill would make rezoning decisions "administrative" instead of "legislative," which would mean they are not subject to ...
Pharmaceutical giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drug pipeline. It came as the boss of the London-listed firm cheered an “excellent” performance ...
Evening Standard on MSN12d
GSK and Oxford researchers to create cancer vaccine to stop disease developingGSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines.
Strong full-year trading and an improving outlook have propelled GSK's share price higher, as Royston Wild explains.
Harvey Jones has something to celebrate after a positive set of results boosted the GSK share price after a disappointing run ...
Pharmaceutical giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drug pipeline.
The pharma giant hiked its 2031 sales forecast to more than £40bn, up from £38bn, after reporting better than forecast fourth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results